NME6
Nucleoside diphosphate kinase 6
Also known as: IPIA-ALPHA, NDK6_HUMAN, NM23-H6
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75414
- Gene
- NME6
- Ensembl
- ENSG00000172113
- Chromosome
- 3
- Canonical length
- 186 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Vesicles
OverviewNCBI Gene
Nucleoside diphosphate (NDP) kinases (EC 2.7.4.6), such as NME6, are ubiquitous enzymes that catalyze transfer of gamma-phosphates, via a phosphohistidine intermediate, between nucleoside and dioxynucleoside tri- and diphosphates (Mehus et al., 1999 [PubMed 10453732]).[supplied by OMIM, Jul 2010]
Canonical amino-acid sequenceUniProt
186 residues, UniProt reviewed canonical sequence.
>O75414|NME6
1 MASILRSPQA LQLTLALIKP DAVAHPLILE AVHQQILSNK FLIVRMRELL WRKEDCQRFY
61 REHEGRFFYQ RLVEFMASGP IRAYILAHKD AIQLWRTLMG PTRVFRARHV APDSIRGSFG
121 LTDTRNTTHG SDSVVSASRE IAAFFPDFSE QRWYEEEEPQ LRCGPVCYSP EGGVHYVAGT
181 GGLGPALocalizationUniProt · AlphaFold · HPA
Whether an antibody against NME6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 17 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 17 nTPM
- tongue: 16 nTPM
- choroid plexus: 14 nTPM
- fallopian tube: 14 nTPM
- placenta: 13 nTPM
- tonsil: 13 nTPM
Single-cell type
- cardiomyocytes: 76 nCPM
- cytotrophoblasts: 61 nCPM
- migrating cytotrophoblasts: 55 nCPM
- extravillous trophoblasts: 50 nCPM
- hofbauer cells: 46 nCPM
- esophageal apical cells: 36 nCPM
Immune cell
- eosinophil: 77 nTPM
- basophil: 48 nTPM
- memory B-cell: 44 nTPM
- non-classical monocyte: 42 nTPM
- gdT-cell: 41 nTPM
- NK-cell: 41 nTPM
Brain region
- cerebellum: 23 nTPM
- choroid plexus: 22 nTPM
- hippocampal formation: 19 nTPM
- thalamus: 18 nTPM
- midbrain: 17 nTPM
- hypothalamus: 17 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.36
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.26
- DepMap mean gene effect
- -0.17
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- CTP biosynthetic process
- GTP biosynthetic process
- negative regulation of cell growth
- negative regulation of mitotic nuclear division
- nucleotide metabolic process
- UTP biosynthetic process
- pyrimidine ribonucleotide salvage
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NME6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NME6 as an antibody target. Whether an autoantibody or antibody against NME6 could matter depends on whether native NME6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NME6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NME6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...